You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it.
NO
YES

HIGHLIGHTS

EVENTS

Kedrion Biopharma supports the 2020 Primary Immunodeficiency Week

The company stands alongside the global PI community

read more 

EVENTS

World Hemophilia Day: socially distant but still united with patients

Now more than ever, Kedrion is renewing its commitment to those who live with this rare disorder

read more 
  1. CORPORATE - 18-01-2016

    A brand new location for KEDPlasma donors in the very center of Fürth

    Plasma collected is turned into life-saving therapies to serve patients in Germany and worldwide

    read more 
  2. CORPORATE - 08-01-2016

    KEDPlasma acquires two plasma centers from ImmunoTek LLC in the US

    The acquisition is part of a five-year growth plan of supplying highest-quality plasma to Kedrion Biopharma

    read more 
  3. CORPORATE - 07-01-2016

    Human rabies Ig meets primary endpoint in U.S. pivotal phase 2/3 clinical trial

    Strategic agreement between Kedrion and Kamada for its clinical development and marketing

    read more 
  4. EVENTS - 07-12-2015

    Hemophilia A. SIPPET study selected by the American Society of Hematology

    Presented at the ASH Congress in Orlando, it was chosen from amongst approximately three thousand studies

    read more 

Pages

For more information please contact: pressoffice@kedrion.com